Lundbeck is a global pharmaceutical company specializing in brain disease.Lundbeck is one of Denmark’s most research-intensive enterprises. We employ more than 1,200 highly-trained specialists in our research and development units. Each year, Lundbeck ploughs back around 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from brain diseases. Lundbeck markets a number of different pharmaceuticals for the treatment of brain diseases. The most recently launched compounds include: Brintellix® (depression), Cipralex/Lexapro® (depression), Abilify Maintena® (schizophrenia), Selincro® (alcohol dependence), Azilect® (Parkinson’s disease), Xenazine® (chorea associated with Huntington's disease), Sabril® (epilepsy) and Onfi® (Lennox-Gastaut syndrome).